Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

14.35 +0.09 (+0.63%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 63,643
Open 14.04
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 14.26
Today's Range 14.35 - 14.46
52wk Range 13.18 - 21.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits. 
Via InvestorPlace

Performance

YTD
-7.54%
-7.54%
1 Month
-7.30%
-7.30%
3 Month
-14.02%
-14.02%
6 Month
+3.68%
+3.68%
1 Year
-7.54%
-7.54%

More News

Read More
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
Via Investor's Business Daily
Current Analysis: Eisai Co Ltd (ESAIY)
Via Talk Markets
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
Via Benzinga
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
Via Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
Via Investor's Business Daily
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Via Investor's Business Daily
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
Via Investor's Business Daily
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Via Talk Markets
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Via Investor's Business Daily
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
Via Investor's Business Daily
3 Stocks to Buy That Could Be the Next Biotech Breakthrough
Via InvestorPlace
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
Via InvestorPlace
7 A-Rated Stocks to Buy for April 2023
Via InvestorPlace
7 Core Stocks to Build a Solid Portfolio Around
Via InvestorPlace
7 Smart Stock Picks for Cautious Investors
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.